Filing Details

United States Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) BIOSTAR ANGEL STEM CELL CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) None (CUSIP Number) 419 Hindry Avenue, Suite E Inglewood, California 90301 ------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 16, 2018 ----------------------------------------------------- (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

====================================================================== CUSIP NO. None 13D Page 2 1. Name of Reporting Persons: NATURE CELL CO. LTD. ------------------------------------------------------------------- 2. Check the appropriate box if a member of a group: (a) (b) ------------------------------------------------------------------- 3. SEC use only ------------------------------------------------------------------- 4. Sourt of Funds PF ------------------------------------------------------------------- 5. Check if disclosure of legal proceeding is required pursuant to Itmes 2(d) or 2(e) [ ] ------------------------------------------------------------------- 6. Citizenship or place of organization: Republic of Korea ------------------------------------------------------------------- NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7. Sole Voting Power: 2,500,000 shares common directly owned ------------------------------------------------------------------- 8. Shared Voting Power: 0 ------------------------------------------------------------------- 9. Sole Dispositive Power: 2,500,000 shares ------------------------------------------------------------------- 10. Shared Dispositive Power: 0 ------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person 2,500,000 shares common ------------------------------------------------------------------- 12. Check if The Aggregate Amount in Row 11 Excludes Certain Shares. / / [ ] ------------------------------------------------------------------- 13. Percent of Class Represented by Amount in Row 11 23.4% (based on 10,680,000 shares outstanding) ------------------------------------------------------------------- 14. Type of Reporting Person: Corporation ====================================================================== CUSIP NO. None 13D Page 3 Item 1 Security and Issuer (a) Name of Issuer: Biostar Angel Stem Cell Corporation (b) Address of Issuer's 419 Hindry Avenue, Suite E Inglewood, CA 90201 (c) Common stock, $0.0001 par value per share ------------------------------------------------------------------- Item 2 Identity and Background (a) Name of Person Filing: Nature Cell Co. Ltd. (b) Address of Principal Business or, if none, Residence: 5F, 10 Gukhoedae-ro 76 Gil Yeongdeungpo-gu Seoul, Republic of Korea 07238 (c) Principal occupation or employment: manufacturing and sales of food and beverage products and life science products. It also conducts research and development on stem cell related science, including clinical trials. (d) None (e) None (f) Citizenship: Republic of Korea ------------------------------------------------------------------- Item 3. Source and Amount of Funds or Other Consideration corporate funds ------------------------------------------------------------------- Item 4. Purpose of transaction invesment in issuer with change in control of company ------------------------------------------------------------------- Item 5. Interest in Securities of Issuer (a) As of the filing date of the Schedule 13D, R Bio Co Ltd. (i) is the beneficial owner and (ii) has sole power to vote (iii) 2,500,000 shares of common stock which represents approximately 23.4% of the shares of common stock deemed to be outstanding pursuant to Rule 13d-1(j). (b) The responses to Items 7-11 of the cover page of this Schedule 13D are incorporated herein. (c) Except as set forth or incorporated herein, no other transaction in the common stock has been effected during the past 60 days. (d) Not applicable. (e) Not applicable. ------------------------------------------------------------------- Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer Not applicable. ------------------------------------------------------------------- Item 7. Materials to Be Filed as Exhibits Not applicable. ------------------------------------------------------------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. NATURE CELL CO.LTD. Dated: March 6, 2018 By: /s/ Ra, Jeong-Chan -------------------------------------- Ra, Jeong-Chan